Mather Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mather Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$140K	Buy	2,337 +970	+71%	+$61.1K	﹤0.01%	877
2026 Q2	$78.2K	Buy	1,367 +1,004	+277%	+$55K	﹤0.01%	998
2026 Q1	$20.5K	Buy	+363	New	+$21.2K	﹤0.01%	1272
2025 Q2	–	Sell	-14	Closed	-$990	–	742
2025 Q1	$990	Buy	14 +11	+367%	+$740	﹤0.01%	1642
2024 Q4	$197	Sell	3 -17	-85%	-$1.14K	﹤0.01%	1700
2024 Q3	$1.41K	Sell	20 -9	-31%	-$752	﹤0.01%	1526
2024 Q2	$2.53K	Buy	29 +13	+81%	+$1.08K	﹤0.01%	1823
2024 Q1	$1.54K	Buy	+16	New	+$1.43K	﹤0.01%	1578

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Covea Finance Paris, France $3.07B AUM 27.46% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

Mather Group's BMRN Position: Q3 2026 in Review

Mather Group increased its BioMarin Pharmaceuticals (BMRN) stake by 71% in Q3 2026, buying an estimated $61.1K and bringing the position to 2,337 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #877.

Mather Group first reported a position in BMRN in Q1 2024 and has held it in 8 quarters since. 75 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Mather Group held 2,337 shares of BioMarin Pharmaceuticals worth $140K as of Q3 2026.
Mather Group bought 970 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $61.1K.
BioMarin Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #877 holding.
Mather Group first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
75 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.